<DOC>
	<DOCNO>NCT00111540</DOCNO>
	<brief_summary>This open label study design assess long term glucose control , measure hemoglobin A1c ( HbA1c ) evaluate long term safety tolerability subject type 2 diabetes mellitus receive subcutaneously inject exenatide administer twice day .</brief_summary>
	<brief_title>Study Examine Effect Glucose Control Safety/Tolerability Exenatide Given Two Times Day Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>The subject HbA1c value &lt; =11.0 % The subject body mass index ( BMI ) 25 kg/m^2 45 kg/m^2 , inclusive Is currently treat certain medication , include exogenous insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>exendin-4</keyword>
</DOC>